NLRP3 and COVID-19: In VitD3 treated COVID-19 patients, the reduction in the levels of NLRP3 and IL-1β were associated with a reduction in D-dimer (P = 0.052 and P<0.001 for Fig 4A and 4D, respectively), IL-6 (P = 0.024 and P<0.001 for Fig 4B and 4E, respectively), and IL-17 (P = 0.024 and P<0.001 for Fig 4C and 4F, respectively).